Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA.

Published 04/04/2026

Research record: Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA.

Published in Infect Dis Ther; first publication date 2026-04-04. PMID 41934527.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-04-04

Updated

2026-10-20

Disclaimer

professional use

References